{"id":92,"date":"2017-09-19T16:23:22","date_gmt":"2017-09-19T16:23:22","guid":{"rendered":"https:\/\/wordpress-dev.med.unc.edu\/millerlab\/?page_id=92"},"modified":"2018-12-27T11:07:46","modified_gmt":"2018-12-27T16:07:46","slug":"publications","status":"publish","type":"page","link":"https:\/\/www.med.unc.edu\/pathology\/millerlab\/publications\/","title":{"rendered":"Publications"},"content":{"rendered":"
\n
\n

CRM Lab NCBI Bibliography<\/a><\/h2>\n

2018<\/h3>\n
    \n
  1. Koehler JW*, Miller AD*, Miller CR<\/strong>*, Porter B*, Aldape K, Beck J, Brat D, Cornax I, Corps K, Frank C, Giannini C, Horbinski C, Huse JT, O\u2019Sullivan MG, Rissi DR, Simpson RM, Woolard K, Shih JH, Mazcko C, Gilbert MR, LeBlanc AK. A revised diagnostic classification of canine glioma: Towards validation of the canine glioma patient as a naturally occurring preclinical model for human glioma.\u00a0 Journal of Neuropathology and Experimental Neurology.\u00a0 77(11):1039-1054 Nov 2018.\u00a0 PMID: 30239918<\/a>\u00a0 PMCID: PMC6181180<\/a>\u00a0 *Contributed equally<\/li>\n
  2. Kesarwani P, Prabhu A, Kant S, Kumar P, Graham SF, Buelow K, Wilson G, Miller CR<\/strong>, Chinnaiyan P. Tryptophan metabolism contributes to radiation-induced immune checkpoint reactivation in glioblastoma. Clinical Cancer Research.\u00a0 24(15):3632-3643\u00a0Aug 2018.\u00a0 PMID: 29691296<\/a><\/li>\n
  3. Okolie O, Irvin DM<\/strong>, Bago JR, Sheets K, Satterlee A, Carey-Ewend AG, Lettry V, Dimitru R, Elton S, Ewend MG, Miller CR<\/strong>, Hingtgen SD.\u00a0 Intra-cavity stem cell therapy inhibits tumor progression in a novel murine model of medulloblastoma surgical resection.\u00a0 PLoS One.\u00a0 13(7):e0198596 Jul 2018.\u00a0 PMID: 29990322<\/a>\u00a0PMCID: PMC6038981<\/a><\/li>\n
  4. McNeill RS<\/strong>, Stroobant EE<\/strong>, Smithberger E<\/strong>, Canoutas DA<\/strong>, Butler MK<\/strong>, Shelton AK<\/strong>, Patel SD<\/strong>, Limas JC, Skinner KR<\/strong>, Bash RE<\/strong>, Schmid RS<\/strong>, Miller CR<\/strong>.\u00a0 PIK3CA missense mutations promote glioblastoma pathogenesis, but do not enhance targeted PI3K inhibition.\u00a0 PLoS One.\u00a0 13(7):e0200014 Jul 2018.\u00a0 PMID: 29975751<\/a>\u00a0 PMCID: PMC6033446<\/a><\/li>\n
  5. Galanis E, Anderson SK, Miller CR<\/strong>, Sarkaria JN, Jaeckle K, Buckner JC, Ligon KL, Ballman KV, Moore DF Jr, Nebozhyn M, Loboda A, Schiff D, Ahluwalia MS, Lee EQ, Gerstner ER, Lesser GJ, Prados M, Grossman SA, Cerhan J, Giannini C, Wen PY, Alliance for Clinical Trials in Oncology and Adult Brain Tumor Consortium (ABTC). Phase I\/II trial of vorinostat combined with temozolomide and radiation therapy for newly diagnosed glioblastoma: Results of Alliance N0874\/ABTC 02.\u00a0 Neuro-oncology.\u00a0 20(4):546-556 Mar 2018.\u00a0 PMID: 29016887<\/a>\u00a0 PMCID:\u00a0 PMC5909661<\/a><\/li>\n
  6. Danussi C, Bose P, Parthasarathy PT, Silberman PC, Van Arnam JS, Vitucci M<\/strong>, Tang OY, Heguy A, Chan TA, Riggins GJ, Sulman EP, Lang F, Creighton CJ, Deneen B, Miller CR<\/strong>, Picketts DJ, Kannan K, Huse JT. Atrx inactivation drives disease-defining phenotypes in glioma cells of origin through global epigenomic remodeling.\u00a0 Nature Communications.\u00a0 9(1):1057 Mar 2018.\u00a0 PMID: 29535300<\/a> \u00a0PMCID:\u00a0 PMC5849741<\/a><\/li>\n
  7. Graham-Gurysh EG, Moore KM, Satterlee AB, Sheets KT, Lin FC, Bachelder EM, Miller CR<\/strong>, Hingtgen S, Ainslie KM. Sustained delivery of doxorubicin via acetalated dextran scaffold prevents glioblastoma recurrence after surgical resection.\u00a0 Molecular Pharmaceutics.\u00a0 15(3):1309-1318 Mar\u00a0 PMID: 29342360<\/a>\u00a0 PMCID:\u00a0 PMC5999333<\/a><\/li>\n
  8. Connolly NP, Shetty AC, Stokum JA, Hoeschele I, Siegel MB, Miller CR<\/strong>, Kim AJ, Ho CY, Davila E, Simard JM, Devine SE, Rossmeisl JH, Holland EC, Winkles JA, Woodworth GF. Cross-species transcriptional analysis reveals conserved and host-specific neoplastic processes in mammalian glioma.\u00a0 Scientific Reports.\u00a0 8(1):1180 Jan 2018.\u00a0 PMID: 29352201<\/a>\u00a0 PMCID: PMC5775420<\/a><\/li>\n
  9. Wu J<\/strong>, Frady LN<\/strong>, Bash RE<\/strong>, Cohen SM, Schorzman AN, Su YT, Irvin DM<\/strong>, Zamboni WC, Wang X, Frye SV, Ewend MG, Sulman EP, Gilbert MR, Earp HS, Miller CR<\/strong>. MerTK as a therapeutic target in glioblastoma.\u00a0 Neuro-oncology. 20(1):92-102 Jan 2018.\u00a0 PMID: 28605477<\/a> \u00a0PMCID:\u00a0 PMC5761530<\/a><\/li>\n<\/ol>\n

    2017<\/h3>\n
      \n
    1. Khagi S, Miller CR<\/strong>. Putting \u201cmultiforme\u201d back into glioblastoma: intratumoral transcriptome heterogeneity is a consequence of its complex morphology.\u00a0 Neuro-oncology.\u00a0 Neuro-oncology.\u00a0 19(12):1570-1571 Nov 2017.\u00a0 PMID: 29016836<\/a>\u00a0 PMCID: PMC5716077<\/a><\/li>\n
    2. McNeill RS<\/strong>, Canoutas DA<\/strong>, Stuhlmiller TJ, Dhruv HD, Irvin DM<\/strong>, Bash RE<\/strong>, Angus SP, Herring LE, Simon JM, Skinner KR<\/strong>, Limas JC, Chen X, Schmid RS<\/strong>, Siegel MB, Van Swearingen AED, Hadler MJ<\/strong>, Sulman EP, Sarkaria JN, Anders CK, Graves LM, Berens ME, Johnson GL, Miller CR<\/strong>. Combination therapy with potent PI3K and MAPK inhibitors overcomes adaptive kinome resistance to single agents in preclinical models of glioblastoma.\u00a0 Neuro-oncology.\u00a0 19(11):1469-1480 Oct 2017.\u00a0 PMID: 28379424<\/a> \u00a0PMCID:\u00a0 PMC5737415<\/a><\/li>\n
    3. Van Swearingen AED, Sambade MJ, Siegel MB, Sud S, McNeill RS,<\/strong> Bevill SM, Chen X, Bash RE, Mounsey L, Golitz BT, Santos C, Deal A, Parker JS, Rashid N, Miller CR<\/strong>, Johnson GL, Anders CK. Combined kinase inhibitors of MEK1\/2 and either PI3K or PDGFR are efficacious in intracranial triple-negative breast cancer.\u00a0 Neuro-oncology.\u00a0 19(11):1481-1493 Oct 2017.\u00a0 PMID: 28486691<\/a> \u00a0PMCID:\u00a0 PMC5737524<\/a><\/li>\n
    4. Vitucci M<\/strong>*,\u00a0Irvin DM<\/strong>*,\u00a0McNeill RS<\/strong>,\u00a0Schmid RS<\/strong>, Simon JM, Dhruv HD, Siegel MB,\u00a0Werneke AM<\/strong>,\u00a0Bash RE<\/strong>, Kim S, Berens ME,\u00a0Miller CR<\/strong>.\u00a0 Genomic profiles of low-grade murine gliomas evolve during progression to glioblastoma.\u00a0 Neuro-oncology.\u00a0 19(9):1237-1257 Sep 2017.\u00a0 *Co-first authors.\u00a0PMID: 28398584<\/a> PMCID:\u00a0 PMC5570221<\/a><\/li>\n
    5. Bago JR, Okolie O, Dumitru R, Ewend MG, Parker JS, Vander Werff R, Underhill TM,\u00a0Schmid RS<\/strong>,\u00a0Miller CR<\/strong>, Hingtgen SD. Tumor-homing cytotoxic human induced neural stem cells for cancer therapy. Science Translational Medicine. 9(375):eaah6510 Feb 2017. PMID:\u00a028148846<\/a><\/li>\n
    6. Irvin DM<\/strong>,\u00a0McNeill RS<\/strong>,\u00a0Bash RE<\/strong>,\u00a0Miller CR<\/strong>. Intrinsic astrocyte heterogeneity influences tumor growth in glioma mouse models. Brain Pathology. 27(1):36-50 Jan 2017. PMID: 26762242<\/a> \u00a0PMCID:\u00a0 PMC5322824<\/a><\/li>\n<\/ol>\n<\/div>\n

      2016<\/h3>\n<\/div>\n
        \n
      1. Okolie O, Bago JR,\u00a0Schmid RS<\/strong>,\u00a0Irvin DM<\/strong>,\u00a0Bash RE,<\/strong>\u00a0Miller CR<\/strong>*, Hingtgen SD*.\u00a0 Reactive astrocytes potentiate tumor aggressiveness in murine glioma resection and recurrence model.\u00a0 Neuro-oncology. \u00a018(12):1622-1633 Dec 2016.\u00a0\u00a0*Co-senior authors\u00a0\u00a0PMID: 27298311<\/a>\u00a0 PMCID: PMC5791515<\/a><\/li>\n
      2. McNeill RS<\/strong>,\u00a0Irvin DM<\/strong>,\u00a0Miller CR<\/strong>.\u00a0 BRAF mutations open doors to ENU-induced gliomagenesis.\u00a0 American Journal of Pathology. \u00a0186(10):2551-2554 Oct 2016.\u00a0 PMID: 27543966<\/a>\u00a0 PMCID: PMC5222976<\/a><\/li>\n
      3. LeBlanc AK, Mazcko C, Brown DB, Koehler JW, Miller AD,\u00a0Miller CR<\/b>, Bentley RT, Packer RA, Breen M, Boudreau B, Levine JM, Simpson MR, Halsey C, Kisseberth W, Rossmeisl JH, Dickinson PJ, Fan T, Corps K, Aldape K, Puduvalli V, Gilbert MR.\u00a0 Creation of an NCI Comparative Brain Tumor Consortium: Informing the translation of new knowledge from canine to human brain tumor patients. \u00a0Neuro-oncology.\u00a0 18(9):1209-1218 Sep 2016.\u00a0 PMID:\u00a027179361<\/a>\u00a0 PMCID:\u00a0PMC4999002<\/a><\/li>\n
      4. Schmid RS<\/strong>, Simon JM,\u00a0Vitucci M<\/strong>,\u00a0McNeill RS<\/strong>,\u00a0Bash RE<\/strong>,\u00a0Werneke AM<\/strong>,\u00a0Huey L<\/strong>,\u00a0White KK<\/strong>, Ewend MG,\u00a0Wu J<\/strong>,\u00a0Miller CR<\/strong>.\u00a0 Core pathway mutations induce de-differentiation of murine astrocytes into glioblastoma stem cells that are sensitive to radiation, but resistant to temozolomide.\u00a0 Neuro-oncology.\u00a0 18(7):962-973 Jul 2016.\u00a0 PMID:\u00a026826202<\/a>\u00a0 PMCID:\u00a0PMC4896545<\/a><\/li>\n
      5. Bago JR, Alfonso-Pecchio A, Okolie O, Dumitru R, Rinkenbaugh A, Baldwin AS,\u00a0Miller CR<\/strong>, Magness ST, Hingtgen SD.\u00a0 Therapeutically engineered induced neural stem cells are tumor-homing and inhibit progression of glioblastoma.\u00a0 Nature Communications.\u00a0 7:10593 Feb 2016.\u00a0 PMID:\u00a026830441\u00a0<\/a>PMCID:\u00a0PMC4740908<\/a><\/li>\n
      6. Ceccarelli M, Barthel FP, Malta TM, Sabedot TS, Salama SR, Murray BA, Morozova O, Newton Y, Radenbaugh A, Pagnotta SM, Anjum S, Wang J, Manyam G, Zoppoli P, Ling S, Rao A, Grifford M, Cherniack AD, Zhang H, Poisson L, Rao A, Mikkelsen T, Lau CC, Yung WKA, Rabadan R, Huse J, Brat DJ, Lehman N, Rao G, Meyerson M, Beroukhim R, Cooper L, Akbani R, Wrensch M, Haussler D, Aldape KD, Laird PW, Gutmann DH,\u00a0Cancer Genome Atlas Research Network<\/strong>, Noushmehr H, Iavarone A, Verhaak RGW.\u00a0 Molecular profiling reveals biologically discrete subsets and pathways of progression in diffuse glioma.\u00a0 Cell.\u00a0 164(3):550-563 Jan 2016. PMID:\u00a026824661<\/a>\u00a0PMCID: \u00a0PMC4754110<\/a><\/li>\n<\/ol>\n
        \n

        2015<\/h3>\n<\/div>\n
          \n
        1. Prabhu A, Sarcar B,\u00a0Miller CR<\/strong>, Kim SH,\u00a0Nakano I, Forsyth P, Chinnaiyan P.\u00a0 Ras-mediated modulation of pyruvate dehydrogenase activity regulates mitochondrial reserve capacity and contributes to glioblastoma tumorigenesis.\u00a0 Neuro-oncology.\u00a0 17(9):1220-1230 Sep 2015.\u00a0 PMID:\u00a025712957<\/a>\u00a0 PMCID:\u00a0PMC4588752<\/a><\/li>\n
        2. Cancer Genome Atlas Research Network<\/strong>.\u00a0 Comprehensive, integrative genomic analysis of diffuse lower-grade gliomas.\u00a0 New England Journal of Medicine.\u00a0 372(26):2481-2498.\u00a0 Jun 2015.\u00a0 PMID:\u00a026061751<\/a>\u00a0 PMCID:\u00a0PMC4530011<\/a><\/li>\n
        3. McNeill RS<\/strong>,\u00a0Vitucci M<\/strong>,\u00a0Wu J<\/strong>,\u00a0Miller CR<\/strong>.\u00a0 Contemporary murine models in preclinical astrocytoma drug development.\u00a0 Neuro-oncology.\u00a0 17(1):12-28 Jan 2015.\u00a0 PMID:\u00a025246428<\/a>\u00a0 PMCID:\u00a0PMC4483055<\/a><\/li>\n<\/ol>\n

          2014<\/h3>\n
            \n
          1. Galvao RP, Kasina A,\u00a0McNeill RS<\/strong>, Harbin JE, Foreman O, Verhaak RGW, Nishiyama A,\u00a0Miller CR<\/strong>, Zong H.\u00a0 Transformation of quiescent adult oligodendrocyte precursor cells into malignant glioma through a multi-step reactivation process.\u00a0 Proceedings of the National Academy of Science USA.\u00a0 111(40):E4214-E4223 Oct 2014.\u00a0 PMID:\u00a025246577<\/a>\u00a0 PMCID:\u00a0PMC4210043<\/a><\/li>\n
          2. McNeill RS<\/strong>,\u00a0Schmid RS<\/strong>,\u00a0Bash RE<\/strong>,\u00a0Vitucci M<\/strong>,\u00a0White KK<\/strong>,\u00a0Werneke AM<\/strong>,\u00a0Constance BH<\/strong>,\u00a0Huff B<\/strong>,\u00a0Miller CR<\/strong>.\u00a0 Modeling astrocytoma pathogenesis in vitro and in vivo using cortical astrocytes or neural stem cells from conditional, genetically engineered mice.\u00a0 Journal of Visualized Experiments.\u00a0 90:e51763 Aug 2014.\u00a0 PMID:\u00a025146643<\/a><\/li>\n
          3. Huse JT, Wallace M, Aldape KD, Berger MS, Bettegowda C, Brat DJ, Cahill DP, Cloughesy T, Haas-Kogan DA, Marra M,\u00a0Miller CR<\/b>, Nelson SJ, Salama SR, Soffietti R, Wen PY, Yip S, Yen K, Costello JF, Chang S.\u00a0 Where are we now?\u00a0 And where are we going?\u00a0 A report from the Accelerate Brain Cancer Cure (ABC2<\/sup>) low-grade glioma workshop.\u00a0 Neuro-oncology.\u00a0 16(2):173-178 Jan 2014.\u00a0 PMID:\u00a024305708<\/a>\u00a0 PMCID:\u00a0PMC3895389<\/a><\/li>\n<\/ol>\n

            2013<\/h3>\n
              \n
            1. Song Y, Zhang Q, Kutlu B, Difilippantonio S,\u00a0Bash R<\/strong>, Gilbert D, Yin C, O\u2019Sullivan TN, Yang C, Kozlov S, Bullitt E, McCarthy KD, Kafri T, Louis DN,\u00a0Miller CR<\/strong>, Hood L, Van Dyke T.\u00a0 Evolutionary etiology of high-grade astrocytomas.\u00a0 Proceedings of the National Academy of Science USA.\u00a0 110(44):17933-17938 Oct 2013. \u00a0PMID:\u00a024114272<\/a>\u00a0PMCID:\u00a0PMC3816471<\/a><\/li>\n
            2. Brennan CW, Verhaak RGW, McKenna A, Campos B, Noushmehr H, Salama SR, Zheng S, Chakravarty D, Sanborn JZ, Berman SH, Beroukhim R, Bernard B, Wu CJ, Genovese G, Shmulevich I, Barnholtz-Sloan J, Zou L, Vegesna R, Shukla SA, Ciriello G, Yung WK, Zhang W, Sougnez C, Mikkelsen T, Aldape K, Bigner DD, Van Meir EG, Prados M, Sloan A, Black KL, Eschbacher J, Finocchiaro, Friedman W, Andrews DW, Guha A, Iacocca M, O\u2019Neill BP, Foltz G, Myers J, Weisenberger DJ, Penny R, Kucherlapati R, Perou CM, Hayes DN, Gibbs R, Marra M, Mills GB, Lander E, Spellman P, Wilson R, Sander C, Weinstein J, Meyerson M, Gabriel S, Laird PW, Haussler D, Getz G, Chin L, and\u00a0Cancer Genome Atlas Research Network<\/strong>.\u00a0 The somatic genomic landscape of glioblastoma.\u00a0 Cell.\u00a0 155(2):462-477 Oct 2013. \u00a0PMID:\u00a024120142<\/a>\u00a0 PMCID:\u00a0PMC3910500<\/a><\/li>\n
            3. Vitucci M<\/strong>*, Karpinich NO*,\u00a0Bash RE<\/strong>,\u00a0Werneke AM<\/strong>,\u00a0Schmid RS<\/strong>,\u00a0White KK<\/strong>,\u00a0McNeill RS<\/strong>,\u00a0Huff B<\/strong>, Wang S, Van Dyke T,\u00a0Miller CR<\/strong>.\u00a0 Cooperativity between MAPK and PI3K signaling activation is required for glioblastoma pathogenesis.\u00a0 *Co-first authors.\u00a0 Neuro-oncology.\u00a0 15(10):1317-1329 Oct 2013.\u00a0 PMID:\u00a023814263<\/a>\u00a0 PMCID:\u00a0PMC3779038<\/a><\/li>\n<\/ol>\n

              2012<\/h3>\n
                \n
              1. Schmid RS<\/strong>,\u00a0Vitucci M<\/strong>,\u00a0Miller CR<\/strong>.\u00a0 Genetically engineered mouse models of diffuse gliomas.\u00a0 Brain Research Bulletin.\u00a0 88(1):72-79 May 2012.\u00a0 PMID:\u00a021684324<\/a><\/li>\n<\/ol>\n

                2011<\/h3>\n
                  \n
                1. Vitucci M<\/strong>, Hayes DN,\u00a0Miller CR<\/strong>.\u00a0 Gene expression profiling of gliomas:\u00a0 Merging genomic and histopathological classification for personalised therapy.\u00a0 British Journal of Cancer.\u00a0 104(4):545-553 Feb 2011.\u00a0 PMID:\u00a021119666<\/a>\u00a0 PMCID:\u00a0PMC3049580<\/a><\/li>\n<\/ol>\n

                  2010<\/h3>\n
                    \n
                  1. Verhaak RGW, Hoadley KA, Purdom E, Wang V, Qi Y, Wilkerson MD,\u00a0Miller CR<\/strong>, Ding L, Golub T, Mesirov JP, Alexe G, Lawrence M, O\u2019Kelly M, Tamayo P, Weir BA, Gabriel S, Winckler W, Gupta S, Jakkula L, Feiler HS, Hodgson JG, James CD, Sarkaria JN, Brennan C, Kahn A, Spellman PT, Wilson RK, Speed TP, Gray JW, Meyerson M, Getz G, Perou CM, Hayes DN and Cancer Genome Atlas Research Network.\u00a0 Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1.\u00a0 Cancer Cell.\u00a0 17(1):98-110 Jan 2010.\u00a0 PMID:\u00a020129251<\/a>\u00a0 PMCID:\u00a0PMC2818769<\/a><\/li>\n<\/ol>\n

                    2009<\/h3>\n
                      \n
                    1. Miller CR<\/strong>, Karpinich NO, Zhang Q, Bullitt E, Kozlov S, and Van Dyke T.\u00a0 Modeling astrocytomas in a family of inducible genetically engineered mice: implications for preclinical cancer drug development.\u00a0 In: Van Meir EG (ed), CNS Cancer, Models, Prognostic Factors, and Targets, 1st<\/sup>\u00a0Ed., Cambridge: Springer, 2009. \u00a0Chapter 7: Pages 119-145.\u00a0 ISBN\u00a0978-1-60327-552-1<\/a>.<\/li>\n<\/ol>\n","protected":false},"excerpt":{"rendered":"

                      CRM Lab NCBI Bibliography 2018 Koehler JW*, Miller AD*, Miller CR*, Porter B*, Aldape K, Beck J, Brat D, Cornax I, Corps K, Frank C, Giannini C, Horbinski C, Huse JT, O\u2019Sullivan MG, Rissi DR, Simpson RM, Woolard K, Shih JH, Mazcko C, Gilbert MR, LeBlanc AK. A revised diagnostic classification of canine glioma: Towards … Read more<\/a><\/p>\n","protected":false},"author":68816,"featured_media":0,"parent":0,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"","meta":{"_acf_changed":false,"footnotes":"","_links_to":"","_links_to_target":""},"class_list":["post-92","page","type-page","status-publish","hentry","odd"],"acf":[],"yoast_head":"\nPublications - C. Ryan Miller Lab<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.med.unc.edu\/pathology\/millerlab\/publications\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Publications - C. Ryan Miller Lab\" \/>\n<meta property=\"og:description\" content=\"CRM Lab NCBI Bibliography 2018 Koehler JW*, Miller AD*, Miller CR*, Porter B*, Aldape K, Beck J, Brat D, Cornax I, Corps K, Frank C, Giannini C, Horbinski C, Huse JT, O\u2019Sullivan MG, Rissi DR, Simpson RM, Woolard K, Shih JH, Mazcko C, Gilbert MR, LeBlanc AK. A revised diagnostic classification of canine glioma: Towards … Read more\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.med.unc.edu\/pathology\/millerlab\/publications\/\" \/>\n<meta property=\"og:site_name\" content=\"C. Ryan Miller Lab\" \/>\n<meta property=\"article:modified_time\" content=\"2018-12-27T16:07:46+00:00\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data1\" content=\"9 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\/\/www.med.unc.edu\/pathology\/millerlab\/publications\/\",\"url\":\"https:\/\/www.med.unc.edu\/pathology\/millerlab\/publications\/\",\"name\":\"Publications - C. Ryan Miller Lab\",\"isPartOf\":{\"@id\":\"https:\/\/www.med.unc.edu\/pathology\/millerlab\/#website\"},\"datePublished\":\"2017-09-19T16:23:22+00:00\",\"dateModified\":\"2018-12-27T16:07:46+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/www.med.unc.edu\/pathology\/millerlab\/publications\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/www.med.unc.edu\/pathology\/millerlab\/publications\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/www.med.unc.edu\/pathology\/millerlab\/publications\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/www.med.unc.edu\/pathology\/millerlab\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Publications\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/www.med.unc.edu\/pathology\/millerlab\/#website\",\"url\":\"https:\/\/www.med.unc.edu\/pathology\/millerlab\/\",\"name\":\"C. Ryan Miller Lab\",\"description\":\"Department of Pathology and Laboratory Medicine\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/www.med.unc.edu\/pathology\/millerlab\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Publications - C. Ryan Miller Lab","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.med.unc.edu\/pathology\/millerlab\/publications\/","og_locale":"en_US","og_type":"article","og_title":"Publications - C. Ryan Miller Lab","og_description":"CRM Lab NCBI Bibliography 2018 Koehler JW*, Miller AD*, Miller CR*, Porter B*, Aldape K, Beck J, Brat D, Cornax I, Corps K, Frank C, Giannini C, Horbinski C, Huse JT, O\u2019Sullivan MG, Rissi DR, Simpson RM, Woolard K, Shih JH, Mazcko C, Gilbert MR, LeBlanc AK. A revised diagnostic classification of canine glioma: Towards … Read more","og_url":"https:\/\/www.med.unc.edu\/pathology\/millerlab\/publications\/","og_site_name":"C. Ryan Miller Lab","article_modified_time":"2018-12-27T16:07:46+00:00","twitter_card":"summary_large_image","twitter_misc":{"Est. reading time":"9 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.med.unc.edu\/pathology\/millerlab\/publications\/","url":"https:\/\/www.med.unc.edu\/pathology\/millerlab\/publications\/","name":"Publications - C. Ryan Miller Lab","isPartOf":{"@id":"https:\/\/www.med.unc.edu\/pathology\/millerlab\/#website"},"datePublished":"2017-09-19T16:23:22+00:00","dateModified":"2018-12-27T16:07:46+00:00","breadcrumb":{"@id":"https:\/\/www.med.unc.edu\/pathology\/millerlab\/publications\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.med.unc.edu\/pathology\/millerlab\/publications\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/www.med.unc.edu\/pathology\/millerlab\/publications\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.med.unc.edu\/pathology\/millerlab\/"},{"@type":"ListItem","position":2,"name":"Publications"}]},{"@type":"WebSite","@id":"https:\/\/www.med.unc.edu\/pathology\/millerlab\/#website","url":"https:\/\/www.med.unc.edu\/pathology\/millerlab\/","name":"C. Ryan Miller Lab","description":"Department of Pathology and Laboratory Medicine","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.med.unc.edu\/pathology\/millerlab\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"}]}},"_links_to":[],"_links_to_target":[],"_links":{"self":[{"href":"https:\/\/www.med.unc.edu\/pathology\/millerlab\/wp-json\/wp\/v2\/pages\/92","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.med.unc.edu\/pathology\/millerlab\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/www.med.unc.edu\/pathology\/millerlab\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/www.med.unc.edu\/pathology\/millerlab\/wp-json\/wp\/v2\/users\/68816"}],"replies":[{"embeddable":true,"href":"https:\/\/www.med.unc.edu\/pathology\/millerlab\/wp-json\/wp\/v2\/comments?post=92"}],"version-history":[{"count":0,"href":"https:\/\/www.med.unc.edu\/pathology\/millerlab\/wp-json\/wp\/v2\/pages\/92\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.med.unc.edu\/pathology\/millerlab\/wp-json\/wp\/v2\/media?parent=92"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}